Moderna has released the first batch of mRNA-1273, its vaccine against the novel coronavirus identified as the cause of pneumonia cases in Wuhan, China. Vials of mRNA-1273 have been shipped to the National Institute of Allergy and Infectious Diseases (NIAID) to be used in the planned Phase 1 study in the U.S. mRNA-1273 is an […]

Beam Therapeutics has announced aggregate gross proceeds of $207 million from their initial public offering which closed on February 11. Beam is a biotechnology company developing precision genetic medicines through the use of base editing. According to their website, Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, […]

Merck has announced plans to spin-off products from its women’s health, legacy brands and biosimilars businesses into a new, independent, publicly-traded company (NewCo). Merck will continue to benefit from strong growth across its current key pillars of oncology, vaccines, hospital and animal health, while remaining fully committed to investing in R&D and to driving value […]

Seeking Funding for Your Medical Device Startup? Take Advantage of this Key Opportunity for Medical Device Entrepreneurs Seeking Funding to Pitch to an Experienced Panel. Email your Presentation by Feb 12 Include Name, Title, Company, and Contact Info MDGPitchFest@mdgboston.org Four medical device startup entrepreneurs will present each company’s value propositions and fundraising efforts to an […]

On January 28th, Boston-based Akcea Therapeutics and Ionis Pharmaceuticals, headquartered in Carlsbad, CA,  announced positive Phase 2 study results of an oligonucleotide treatment of hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The oligonucleotide, AKCEA-ANGPTL3-LRx, functions by an antisense-mediated reduction of angiopoietin-like 3 (ANGPTL3) protein in the liver. The antisense oligonucleotide is a […]